Table 2.

Treatment (quantile) difference in patients with mild AD dementia at baseline (solanezumab versus placebo, week 80)

		Patients with mild AD dementia at baseline (n = 1322)
		ADAS-Cog14		ADCS-iADL
		Sola vs PBO treatment difference	P value∗	Sola vs PBO treatment difference	P value∗
	All patients	2.13†	.001	1.21†	.045
Percentile	20th	1.06†	.02	0.25†	.59
	30th	1.45†	<.01	0.55†	.22
	40th	2.10†	<.01	1.14†	.04
	60th	2.43†	<.01	1.72†	<.01
	80th	2.56†	<.01	2.16†	.05

^∗P values were based on Wald Test.

^†Values in favor of solanezumab treatment.